TPST - Tempest Therapeutics Inc

TPST - Tempest Therapeutics Inc

https://www.tempesttx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire • 1 month ago • score: 0.04

BRISBANE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. ( Nasdaq: TPST ) , a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended June 30, ...

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

GlobeNewswire • 2 months, 2 weeks ago • score: 0.06

BRISBANE, Calif., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. ( Nasdaq: TPST ) , a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the ...

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

GlobeNewswire • 3 months ago • score: 0.06

BRISBANE, Calif., June 11, 2025 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. ( Nasdaq: TPST ) , a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement ...

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Zacks Commentary • 3 months, 1 week ago • score: -0.25

Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire • 4 months ago • score: 0.09

BRISBANE, Calif., May 13, 2025 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. ( Nasdaq: TPST ) , a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 ...

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

GlobeNewswire • 4 months, 3 weeks ago • score: -0.01

BRISBANE, Calif., April 21, 2025 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. ( Nasdaq: TPST ) , a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S.

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Tempest Therapeutics ( NASDAQ:TPST )

Benzinga • 5 months ago • score: 0.17

Tempest to lead Phase 3 liver cancer trial with free atezolizumab supply from Roche. Scotia Capital downgrades Tempest stock from Sector Outperform to Sector Perform. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.

52W High

$20.67

52W Low

$5.35

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-2.29

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.31

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

4.99

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.11%

Institutions (25–75% balanced)

18.87%

Shares Outstanding

4,440,200

Float

3,887,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-14.52

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.23%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.6651

Previous

0.7485

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025